Curi Bio Announces Technology Acquisition & Product Launch
Portfolio company Curi Bio announced the acquisition of CarTox™ Technology from StemBioSys & Launch of Nautilus™ Optical Mapping System.
Curi helps pharmaceutical partners develop safer, more effective therapeutics by providing drug developers with human-relevant tissue-specific biosystems in the preclinical stage of drug development. The acquisition from StemBioSys of the CarTox™ technology platform for calcium and voltage optical mapping will be commercialized through the launch of the Nautilus™ optical mapping system.
With the Nautilus system, scientists can achieve clinically-relevant electrophysiology and calcium transient measurements in vitro in a high-throughput, reproducible screening format. Curi will make the Nautilus system available to pharmaceutical and research customers as a standalone bioscience instrument, compatible with Curi Bio’s market-leading cloud-based data analytics platforms. Curi will also offer service contracts and partnerships leveraging the system for applications in drug discovery, disease modeling, and safety and efficacy screening.